Kenneth CPA - Alzamend Neuro Senior Finance
| ALZN Stock | USD 0.69 0.02 2.99% |
Executive
Kenneth CPA is Senior Finance of Alzamend Neuro
| Age | 64 |
| Address | 3480 Peachtree Road NE, Atlanta, GA, United States, 30326 |
| Phone | 844 722 6333 |
| Web | https://www.alzamend.com |
Alzamend Neuro Management Efficiency
The company has return on total asset (ROA) of (1.2164) % which means that it has lost $1.2164 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.9296) %, meaning that it created substantial loss on money invested by shareholders. Alzamend Neuro's management efficiency ratios could be used to measure how well Alzamend Neuro manages its routine affairs as well as how well it operates its assets and liabilities. As of the 14th of March 2025, Return On Tangible Assets is likely to grow to -17.21. In addition to that, Return On Capital Employed is likely to drop to 4.19. As of the 14th of March 2025, Debt To Assets is likely to grow to 0.95, while Net Tangible Assets are likely to drop about 3.3 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Renate Gloggner | Molecular Partners AG | 55 | |
| JD Esq | Terns Pharmaceuticals | 56 | |
| Robert JD | Senti Biosciences | 57 | |
| Norah Conway | Alector | N/A | |
| Soojin Kim | Inozyme Pharma | N/A | |
| Michael Steel | Adverum Biotechnologies | N/A | |
| Pamela Trail | Molecular Partners AG | 69 | |
| Robyn MA | Acumen Pharmaceuticals | N/A | |
| Gabriel MD | Solid Biosciences LLC | 47 | |
| FASCP MD | Inozyme Pharma | 70 | |
| Heikki Jouttijarvi | Adverum Biotechnologies | N/A | |
| MS MBA | Alector | 50 | |
| Matthew Beck | Hookipa Pharma | N/A | |
| Mark MBA | X4 Pharmaceuticals | 61 | |
| Jessie Hanrahan | Solid Biosciences LLC | 48 | |
| Danielle JD | Alector | N/A | |
| Bill PharmD | Adverum Biotechnologies | N/A | |
| Prof MD | Day One Biopharmaceuticals | 55 | |
| Neel Anand | Kezar Life Sciences | N/A | |
| Anne DVM | Molecular Partners AG | N/A | |
| Jay Cross | Senti Biosciences | 54 | |
Management Performance
| Return On Equity | -10.93 | ||||
| Return On Asset | -1.22 |
Alzamend Neuro Leadership Team
Elected by the shareholders, the Alzamend Neuro's board of directors comprises two types of representatives: Alzamend Neuro inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Alzamend. The board's role is to monitor Alzamend Neuro's management team and ensure that shareholders' interests are well served. Alzamend Neuro's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Alzamend Neuro's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kenneth CPA, Senior Finance | ||
| David Katzoff, Chief Officer | ||
| Stephan Jackman, CEO Director | ||
| Milton III, Founder Chairman | ||
| Henry Esq, General VP |
Alzamend Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Alzamend Neuro a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -10.93 | ||||
| Return On Asset | -1.22 | ||||
| Current Valuation | 4.53 M | ||||
| Shares Outstanding | 6.6 M | ||||
| Shares Owned By Insiders | 3.08 % | ||||
| Shares Owned By Institutions | 1.71 % | ||||
| Number Of Shares Shorted | 52.81 K | ||||
| Price To Book | 1.23 X | ||||
| EBITDA | (9.89 M) | ||||
| Net Income | (9.95 M) |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alzamend Neuro. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. To learn how to invest in Alzamend Stock, please use our How to Invest in Alzamend Neuro guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alzamend Neuro. If investors know Alzamend will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alzamend Neuro listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Alzamend Neuro is measured differently than its book value, which is the value of Alzamend that is recorded on the company's balance sheet. Investors also form their own opinion of Alzamend Neuro's value that differs from its market value or its book value, called intrinsic value, which is Alzamend Neuro's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alzamend Neuro's market value can be influenced by many factors that don't directly affect Alzamend Neuro's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alzamend Neuro's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alzamend Neuro is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alzamend Neuro's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.